Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.

Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D.

JAMA. 2012 Apr 18;307(15):1593-601. doi: 10.1001/jama.2012.454.

2.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.

Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S.

Lung Cancer. 2014 Dec;86(3):350-7. doi: 10.1016/j.lungcan.2014.09.017. Epub 2014 Sep 30.

PMID:
25439437
3.

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D.

Cancer. 2013 Jun 1;119(11):2048-60. doi: 10.1002/cncr.28022. Epub 2013 Apr 5.

4.

Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.

Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Bowles EJ, Loggers ET, Menter A.

J Thorac Oncol. 2014 May;9(5):692-701. doi: 10.1097/JTO.0000000000000127.

5.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH.

Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489.

PMID:
24356624
6.

Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.

Spence MM, Hui RL, Chang JT, Schottinger JE, Millares M, Rashid N.

J Manag Care Spec Pharm. 2017 Feb;23(2):195-205. doi: 10.18553/jmcp.2017.23.2.195.

7.

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S, Asmar L.

J Thorac Oncol. 2009 Dec;4(12):1537-43. doi: 10.1097/JTO.0b013e3181c0a2f4.

9.

Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.

Ezer N, Smith CB, Galsky MD, Mhango G, Gu F, Gomez J, Strauss GM, Wisnivesky J.

Radiother Oncol. 2014 Aug;112(2):272-8. doi: 10.1016/j.radonc.2014.07.014. Epub 2014 Aug 20.

PMID:
25150635
10.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group.

Lung Cancer. 2012 Jun;76(3):362-7. doi: 10.1016/j.lungcan.2011.12.005. Epub 2012 Jan 14.

11.

The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.

Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1159-66. doi: 10.1007/s00280-014-2590-x. Epub 2014 Sep 23.

PMID:
25245821
12.
13.

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY.

J Clin Oncol. 2015 Jul 1;33(19):2197-204. doi: 10.1200/JCO.2014.59.4424. Epub 2015 May 26.

PMID:
26014294
14.

BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.

Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C.

J Thorac Oncol. 2011 Jan;6(1):109-14. doi: 10.1097/JTO.0b013e3181f94ad4.

15.

Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.

Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH.

J Thorac Oncol. 2012 Sep;7(9):1361-8. doi: 10.1097/JTO.0b013e318260e106.

16.

Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.

Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ.

J Thorac Oncol. 2013 Mar;8(3):338-45. doi: 10.1097/JTO.0b013e318282ded5.

17.

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).

Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S.

Lung Cancer. 2015 Feb;87(2):136-40. doi: 10.1016/j.lungcan.2014.12.007. Epub 2014 Dec 19.

PMID:
25553650
18.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

19.

Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.

Hata A, Katakami N, Tanaka K, Takeshita J, Matsumoto T, Monden K, Nagata K, Masago K, Kaji R, Fujita S, Tachikawa R, Otsuka K, Otsuka K, Tomii K.

Anticancer Res. 2014 Jan;34(1):275-81.

PMID:
24403474
20.

Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.

Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, Brahmer JR, Johnson DH, Sandler A.

J Thorac Oncol. 2012 Nov;7(11):1707-12. doi: 10.1097/JTO.0b013e318265b500.

Supplemental Content

Support Center